Fever News and Research

RSS

Growing concern in Asia over resistance to artemisinin-based antimalarial medicines

"Growing resistance to a key anti-malarial drug derived from a shrub used in traditional Chinese medicine is threatening to roll back gains made in combating the disease," according to experts attending a U.N.-sponsored malaria conference that concluded on Friday in Sydney, Australia, the U.N. News Centre reports.

6 Nov 2012

Adenovirus detection not uncommon among children with Kawasaki disease

Clinicians should take caution when diagnosing a child who has a high fever and whose tests show evidence of adenovirus, and not assume the virus is responsible for Kawasaki-like symptoms. According to a new study from Nationwide Children's Hospital appearing in Clinical Infectious Diseases, adenovirus detection is not uncommon among children with Kawasaki disease.

5 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Procalcitonin good marker of bacteremia in children with central lines

High procalcitonin levels are a good indicator of bacteremia in children with a central venous catheter who present to the emergency department with fever, suggest study findings.

30 Oct 2012

Pfizer receives FDA approval for Synribo to treat chronic myelogenous leukemia

The U.S. Food and Drug Administration today approved Synribo (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.

29 Oct 2012

Allergies and hygiene: an interview with Sally Bloomfield

Allergies occur when the body overreacts to substances in our environment, such as pollen, dust mites and so forth. What happens is that when we are exposed to these potential threats, the immune system should react, deal with it, and then shut down.

26 Oct 2012

CUMC researchers develop first true mouse model of typhoid infection

Columbia University Medical Center (CUMC) researchers have created the first true mouse model of typhoid infection. The development promises to advance the study of typhoid and the creation of new vaccines against the infection, which remains a major health threat in developing countries.

26 Oct 2012

Durata completes target enrollment in dalbavancin Phase 3 trial for ABSSSI

Durata Therapeutics today announced that it has completed its target enrollment for DISCOVER 2 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response"), the second global, Phase 3 clinical trial of Durata's lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria.

26 Oct 2012

New method of testing for West Nile virus

While the United States has largely been spared the scourge of mosquito-borne diseases endemic to the developing world-including yellow fever, malaria and dengue fever-mosquito-related illnesses in the US are on the rise. One pathogen of increasing concern in the U.S. is an arbovirus known as West Nile.

24 Oct 2012

NEJM report on best options for safe, effective patient treatment against fungal meningitis

As the number of fungal meningitis cases continues to rise, physicians across the country are faced with how best to provide the early treatment that can save lives.

24 Oct 2012

Abbott announces results from HUMIRA clinical studies on ulcerative colitis

Abbott (NYSE: ABT) today announced results from an analysis of three-year long-term data from an ongoing open-label extension of the HUMIRA (adalimumab) ULTRA 1 and ULTRA 2 studies.

23 Oct 2012

Sanofi presents overview of Phase II and III trials for quadrivalent influenza vaccine

Sanofi Pasteur, the vaccines division of Sanofi, presented today an overview of Phase II and Phase III clinical trials for its investigational quadrivalent influenza vaccine (QIV).

23 Oct 2012

Researchers discover Hyalomma ticks in migratory birds

A type of haemorrhagic fever (Crimean-Congo) that is prevalent in Africa, Asia, and the Balkans has begun to spread to new areas in southern Europe. Now Swedish researchers have shown that migratory birds carrying ticks are the possible source of contagion.

22 Oct 2012

Chinese herbs may show significant benefits for patients with NSCLC, IPF and influenza

Chinese herbs, including JHQG, BFXL, and BFHX, may show significant benefits for patients with non-small cell lung cancer (NSCLC), idiopathic pulmonary fibrosis (IPF), and influenza.

22 Oct 2012

MRSA-related pneumonia can be effectively treated in half the recommended time

The national practice guideline for treating MRSA-related pneumonia is seven to 21 days. A Henry Ford Hospital study found that effective treatment can be done in half the time.

20 Oct 2012

Henry Ford study evaluates length of treatment for MRSA-related pneumonia

The national practice guideline for treating MRSA-related pneumonia is seven to 21 days. A Henry Ford Hospital study found that effective treatment can be done in half the time.

20 Oct 2012

UCI, Brown work advances quest for novel treatments for inherited disorder

UC Irvine and Brown University researchers have created a new fruit fly model of inherited epilepsy that's providing insights into the mechanisms underlying temperature-dependent seizures while establishing a platform from which to develop therapies for these disorders.

20 Oct 2012

New data shows influenza-associated deaths among children, effectiveness of school vaccinations

New data being presented at IDWeek 2012TM shows the fatal risk that influenza poses even for children without underlying health conditions and the effectiveness of school-based vaccination programs in protecting student populations.

20 Oct 2012

Sanofi Pasteur files Fluzone sBLA with FDA for treatment of influenza

Sanofi Pasteur, the vaccines division of Sanofi, announced today that it has filed a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for a quadrivalent formulation of its Fluzone (Influenza Virus Vaccine).

20 Oct 2012

Novel therapy that uses human stool is safe and highly effective in treating C.diff infection

A novel therapy that uses donated human stool to treat the deadly and contagious C.diff infection is safe and highly effective, according to a Henry Ford Hospital study.

20 Oct 2012

Fever News and Research

Growing concern in Asia over resistance to artemisinin-based antimalarial medicines

Adenovirus detection not uncommon among children with Kawasaki disease

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Procalcitonin good marker of bacteremia in children with central lines

Pfizer receives FDA approval for Synribo to treat chronic myelogenous leukemia

Allergies and hygiene: an interview with Sally Bloomfield

CUMC researchers develop first true mouse model of typhoid infection

Durata completes target enrollment in dalbavancin Phase 3 trial for ABSSSI

New method of testing for West Nile virus

NEJM report on best options for safe, effective patient treatment against fungal meningitis

Abbott announces results from HUMIRA clinical studies on ulcerative colitis

Sanofi presents overview of Phase II and III trials for quadrivalent influenza vaccine

Researchers discover Hyalomma ticks in migratory birds

Chinese herbs may show significant benefits for patients with NSCLC, IPF and influenza

MRSA-related pneumonia can be effectively treated in half the recommended time

Henry Ford study evaluates length of treatment for MRSA-related pneumonia

UCI, Brown work advances quest for novel treatments for inherited disorder

New data shows influenza-associated deaths among children, effectiveness of school vaccinations

Sanofi Pasteur files Fluzone sBLA with FDA for treatment of influenza

Novel therapy that uses human stool is safe and highly effective in treating C.diff infection

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News